Syed OA
Institute of Medical Science, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
ArticleKetamine
Real-World Therapeutic Use of Ketamine in Clinical and Non-Clinical Settings: A Cross-Sectional Survey.
ArticlePsilocybin
Microdosing psychedelics: What, why, when, and how often? Insights from an international survey of people who use psychedelics.
ArticleKetamine
Clinical Predictors of Antidepressant Effects of Ketamine and Esketamine in Treatment-Resistant Unipolar and Bipolar Depression: A Systematic Review.
ArticlePsilocybin
Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial - CORRIGENDUM.
ArticlePsilocybin
Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial.
ArticlePsilocybin
Methodological moderators of psilocybin-assisted therapy in depression: A systematic review and meta-analysis.
ArticleMDMA
Adverse events associated with classic psychedelics and MDMA: a real-world population-based study using the WHO pharmacovigilance database (VigiBase).
ArticlePsilocybin
The effect of psychedelic microdosing on animal behavior: A review with recommendations for the field.
ArticlePsilocybin
Preferences, Perceptions, and Environmental Considerations of Natural and Synthetic Psychedelic Substances: Findings from the Global Psychedelic Survey.
ArticlePsilocybin
Global Trends in Psychedelic Microdosing: Demographics, Substance Testing Behavior, and Patterns of Use.
ArticlePsychedelics
Managing expectations with psychedelic microdosing.
ArticlePsilocybin